Breaking News: Health Headlines from Around the Globe

Key updates from the health sector include Structure Therapeutics' obesity pill showing no liver injury signs, the US CDC's Ebola outbreak warning, and Zealand Pharma's obesity drug trial success. Also, Roche's obesity treatment results are positive, while screwworm detection alarms Texas ranchers. US senators scrutinize Big Tobacco for FDA-related lobbying.

Structure Therapeutics has announced promising results for its experimental GLP-1 obesity pill, with no signs of drug-induced liver injury and continued weight loss even at lower doses. Despite 10.4% of patients discontinuing treatment, this marks a significant development in obesity management.

The United States has pledged an additional $38 million to fight the Ebola outbreak in the Democratic Republic of Congo, as the CDC warns the situation could rival the 2014 West Africa crisis. Including this contribution, the US commitment amounts to over $200 million in direct funding.

Zealand Pharma, collaborating with Roche, has released mid-stage trial data showing high tolerability for its experimental obesity drug, potentially challenging market leaders with a gentler treatment option. Meanwhile, Roche claims a 22.7% average weight loss in a trial for its dual-acting drug, highlighting the competitive obesity treatment landscape.